GlassScriptPhysician profile
Kitren B Sinnathamby
NPI 1295834885
$1,710.46
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $545 · 2021: $463.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $430.72 | 2019-2020 | |
| Pfizer INC. | $258.46 | 2019-2021 | |
| Mylan Specialty L.P. | $179.13 | 2020-2021 | |
| Amarin Pharma, INC. | $177.47 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $155.97 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $73.03 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $71.72 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.37 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.39 | 2019-2020 | |
| Novo Nordisk INC | $48.41 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.25 | 2019-2021 | |
| Lilly USA, LLC | $25.55 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $22.78 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $17.75 | 2019 | |
| Grifols USA, LLC | $16.77 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $14.32 | 2021 | |
| Eisai INC. | $13.76 | 2020 | |
| Glaxosmithkline, LLC. | $12.61 | 2020 | |
| Astellas Pharma US INC | $12.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.88 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kitren Sinnathamby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.